AG2R LA Mondiale Gestion D Actifs Has $1.58 Million Holdings in Kenvue Inc. $KVUE

AG2R LA Mondiale Gestion D Actifs grew its position in Kenvue Inc. (NYSE:KVUE) by 4.7% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 75,683 shares of the company’s stock after acquiring an additional 3,427 shares during the quarter. AG2R LA Mondiale Gestion D Actifs’ holdings in Kenvue were worth $1,584,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of KVUE. GAMMA Investing LLC increased its position in Kenvue by 33.2% in the 1st quarter. GAMMA Investing LLC now owns 24,778 shares of the company’s stock worth $594,000 after purchasing an additional 6,169 shares during the last quarter. Cambridge Investment Research Advisors Inc. increased its position in Kenvue by 4.0% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 106,140 shares of the company’s stock worth $2,545,000 after purchasing an additional 4,034 shares during the last quarter. International Assets Investment Management LLC acquired a new position in Kenvue in the 1st quarter worth about $246,000. Golden State Wealth Management LLC increased its position in Kenvue by 292.0% in the 1st quarter. Golden State Wealth Management LLC now owns 3,081 shares of the company’s stock worth $74,000 after purchasing an additional 2,295 shares during the last quarter. Finally, Robeco Institutional Asset Management B.V. increased its holdings in shares of Kenvue by 2.6% during the 1st quarter. Robeco Institutional Asset Management B.V. now owns 103,091 shares of the company’s stock valued at $2,472,000 after acquiring an additional 2,576 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Price Performance

Shares of NYSE:KVUE opened at $15.00 on Friday. The business has a 50 day moving average price of $17.91 and a 200 day moving average price of $20.79. Kenvue Inc. has a twelve month low of $14.05 and a twelve month high of $25.17. The company has a market cap of $28.78 billion, a price-to-earnings ratio of 20.26, a PEG ratio of 2.16 and a beta of 0.72. The company has a quick ratio of 0.68, a current ratio of 0.98 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, August 7th. The company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.28 by $0.01. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.The firm had revenue of $3.84 billion during the quarter, compared to the consensus estimate of $3.94 billion. During the same quarter in the prior year, the company earned $0.32 EPS. The firm’s revenue for the quarter was down 4.0% compared to the same quarter last year. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Research analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, August 27th. Shareholders of record on Wednesday, August 13th were given a $0.2075 dividend. The ex-dividend date was Wednesday, August 13th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 5.5%. This is an increase from Kenvue’s previous quarterly dividend of $0.21. Kenvue’s dividend payout ratio is 112.16%.

Analysts Set New Price Targets

KVUE has been the topic of a number of analyst reports. The Goldman Sachs Group lowered their price objective on Kenvue from $22.00 to $19.00 and set a “neutral” rating on the stock in a report on Thursday, October 2nd. Redburn Partners set a $22.00 price objective on Kenvue in a report on Friday, September 26th. Rothschild & Co Redburn raised Kenvue from a “neutral” rating to a “buy” rating and lowered their price objective for the company from $22.50 to $22.00 in a report on Friday, September 26th. JPMorgan Chase & Co. lowered their price objective on Kenvue from $24.00 to $21.00 and set an “overweight” rating on the stock in a report on Friday, October 10th. Finally, Royal Bank Of Canada lowered their price objective on Kenvue from $24.00 to $22.00 and set a “sector perform” rating on the stock in a report on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $20.75.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.